Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson’s Disease Cohort

Kenna, Jade E.; Bakeberg, Megan C.; Abonnel, Maddison Y.; Mastaglia, Frank L.; Anderton, Ryan S.

doi:https://doi.org/10.1155/2022/4053665

Parkinson’s Disease

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2022 | Article ID 4053665 | https://doi.org/10.1155/2022/4053665

Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson’s Disease Cohort

Jade E. Kenna,^1,2,3,4Megan C. Bakeberg,⁵Maddison Y. Abonnel,¹Frank L. Mastaglia,^3,4and Ryan S. Anderton^1,6

Academic Editor: Carlo Colosimo

Received12 Aug 2022

Revised07 Nov 2022

Accepted21 Nov 2022

Published25 Nov 2022

Abstract

Background. Gastrointestinal symptoms (GIS) in people with Parkinson’s disease (PwP) are often underreported and may remain untreated. Constipation is a common nonmotor symptom that can adversely affect health-related quality of life (QoL); however, the impact of other GIS has not been adequately investigated. Objectives. To investigate the relationship between QoL and constipation using the Bristol Stool Chart, bowel movement frequency, and a perceived constipation measure; and to explore the relationship between QoL and other GIS in an Australian PD cohort. Methods. The impact of constipation and other GIS on QoL, as measured using the PDQ-39 scale, was assessed in a cohort of 144 (89 males, 55 females) clinic-attending PwP. Constipation was assessed using the Bristol Stool Chart as well as a composite constipation measure, and the Gastrointestinal Symptom Rating Scale (GSRS) was used to rate other GIS. Covariate corrected linear regression models were utilised to determine significant associations between GIS and QoL scores. Results. Individual and combined constipation measures were significantly associated with poorer QoL ( and , respectively). Analysis of GSRS symptom domains showed that in addition to symptoms of gastrointestinal hypomotility, a number of other symptoms such as increased eructation and increased flatus were also associated with poorer QoL. Conclusions. The findings point to the importance of GIS as contributor to health-related QoL in PwP. A better understanding of the relationship between GIS and QoL will help facilitate the development of more effective screening and treatment programs to improve symptom management and QoL for PwP.

1. Introduction

Parkinson’s disease (PD) is a complex, progressive neurodegenerative disorder that was originally typified by its characteristic and clinically defining motor symptoms including, tremor, bradykinesia, rigidity, and postural instability. It is now recognised that a plethora of nonmotor symptoms (NMS) also occur and may antedate the characteristic motor symptoms of the disease [1–3]. These NMS include but are not limited to cognitive decline, mood and sleep disturbances, an impaired sense of smell, and a wide range of gastrointestinal symptoms [3, 4]. In fact, research indicates that the NMS of PD may have a greater impact on health-related quality of life than the cardinal motor symptoms [5, 6]. As PD does not have a cure or treatment to slow disease progression, research needs to focus on identifying factors that can be treated to improve patient quality of life.

Health-related quality of life (QoL) is defined as “the patient’s own perception and self-evaluation regarding the effects of an illness and its consequences on his or her life” [7]. In complex, progressive disorders, like Parkinson’s disease, with a wide range of motor and nonmotor symptoms, QoL is an important factor to consider when managing the disease as each individual will be unique, in terms of the combination of symptoms at any particular time-point in the course of the disease. Although constipation can affect QoL in PwP [6, 8, 9], gastrointestinal symptoms remain as the top underreported [10, 11], and thus, untreated symptoms in PD [5], leading to suboptimal clinical care and poorer QoL [12]. Whereas the adverse effects of other NMS such as cognitive impairment [13, 14] and sleep disturbances [15, 16], on QoL in PD are well-documented, the impact of gastrointestinal symptoms on QoL in PD populations has received relatively little attention in the literature.

Gastrointestinal symptoms (GIS), including constipation and nausea, are reported to be amongst the earliest symptoms to develop in PD, manifesting up to 20 years prior to the clinically defining motor symptoms [17, 18]. It is reported that 60–80% of people with PD (PwP) experience constipation [19], with almost all PwP experiencing GIS at some time throughout their disease course. A positive relationship also exists between inflammatory bowel diseases and the risk of developing PD and has been reported in many populations [20–22]. Additionally, proinflammatory bacterial species in the gut microbiome, which can manifest clinically as GIS, have been shown to be increased in PwP [23–28]. Thus, the link between GIS and PD is well established. As such, a disease-specific Gastrointestinal Dysfunction Scale for PwP has recently been proposed [29]. However, the extent to which GIS specifically impact on QoL in people with PwP remains unclear. Therefore, there is a need to better understand the relationship between constipation and other GIS and QoL in PwP to help facilitate the development of more effective screening and treatment programs and to improve patient quality of life.

The aims of the present study were: (i) to investigate the relationship between QoL and constipation using the Bristol Stool Chart, bowel movement frequency, and a perceived constipation measure; and (ii) to further explore the relationship between QoL and other GIS using the comprehensive Gastrointestinal Symptom Rating Scale (GSRS), in an Australian PD cohort.

2. Materials and Methods

2.1. Ethical Compliance

The study was approved by the Human Research Ethics Committees of The University of Western Australia (RA/4/20/4470) and St. Vincent’s Hospital, Melbourne (LRR137/18). Prior to inclusion in the study, all participants were required to provide written informed consent and were free to withdraw from the study at any time. All work was conducted in accordance with the Declaration of Helsinki (1964).

2.2. Participants

Participants diagnosed with idiopathic PD (n = 144; 89 M/55 F) were recruited from Movement Disorders Clinics at the Perron Institute for Neurological and Translational Science (Perth, WA) and St. Vincent’s Hospital (Melbourne, VIC) and assessed at respective clinics by the same researcher (JK) to mitigate potential bias. All participants were previously examined by a movement disorders neurologist for verification of the diagnosis in accordance with the UK Brain Bank Criteria for idiopathic PD [30], were ambulant, and none were known to have any other neurological disorders.

2.3. Clinical Assessments

Participants were assessed in the “ON” state using the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts I–IV, with a higher score representing greater disease severity. Nonmotor and motor experiences of daily living were evaluated by MDS-UPDRS parts I and II, respectively. The severity of motor symptoms, and motor complications were evaluated by MDS-UPDRS Parts III and IV, respectively, and overall disease severity was rated using the Hoehn and Yahr scale. PD medications were categorised into six medication classes: levodopa (L-DOPA), dopamine agonists (DA), catechol-O-methyl transferase inhibitors (COMT-I) with levodopa, monoamine oxidase inhibitors (MAO-I), anticholinergics, and amantadine, and reported daily dosages were converted into a levodopa equivalent daily dosage (LEDD), as previously described [31]. Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) as previously described [32]. The GSRS is a 15-questionpatient-compiled scale in which gastrointestinal symptoms during the preceding 3 months are evaluated individually on a 0–4 scale.

2.4. Constipation Assessments

This study used three individual measures and one combined measure of constipation. The first individual measure, the Bristol Stool Chart, is an extensively used stool form measurement tool with an ordinal scale of stool types ranging from Type 1 (hardest) to Type 7 (softest). Types 1 and 2 are considered abnormally hard (indicative of constipation), Types 3, 4, and 5 are considered normal, and Types 6 and 7 are considered abnormally loose. The second individual measure recorded was the frequency of bowel movements per day. The third individual measure was a perceived constipation question, where participants were asked whether they considered themselves to suffer from constipation or not and hereon will be referred to as “self-reported constipation.” As constipation refers to hard to pass and/or infrequently passed stool [33], all three individual constipation measures were then coded together, with any individual fitting the criteria for constipation in two or more of the individual constipation measures being coded as “constipated” in the combined measure of constipation.

2.5. Quality of Life Assessment

Participants completed a self-report39-question Parkinson’s disease quality of life (PDQ-39) questionnaire to evaluate Parkinson’s disease specific health-related quality of life over the previous month. The PDQ-39 is one of the most frequently adopted and highly recommended assessments for QoL in individuals with PD [25]. Each question was answered on a 5-stage scale, ranging from 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always/or cannot do at all. This questionnaire measures the following eight domains of quality of life: mobility, activities of daily living, emotional wellbeing, stigma, social support, cognition, communication, and bodily discomfort. Higher scores represented a lower quality of life.

2.6. Statistical Analyses

Statistical analyses were run on IBM SPSS (v. 28.0.1.0, IBM Corporation). Quantitative data were expressed as mean (SD), and categorical variables were expressed as n (%). All variables were assessed for normality using the Kolmogorov–Smirnov and returned significant values (). Differences in mean PDQ-39 total score, when grouped according to constipation and stool measures, were determined using the Mann–Whitney U tests, when grouped into binary variables, and Generalised Linear Models (GLMs), when kept as continuous variables, to correct for covariates. To further investigate associations between GSRS scores and the PDQ-39 total score, naïve and corrected GLMs were utilized. To assess for multicollinearity, the variance inflation factor (VIF) was calculated for all independent variables. For all reported models, VIF values were less than 2. A nominal value of <0.05 was regarded as being statistically significant.

3. Results

3.1. Cohort Demographic and Clinical Data

Demographic and clinical assessment details for the PwP cohort are presented in Table 1. The average age of participants was 65.6 (SD = 9.19), and just over half were males (61.8%). PwP had a mean MDS-UPDRS III motor score of 21.81 (SD = 14.16) and had an average Hoehn and Yahr score of 2.03 (SD = 0.77). Of the participants, the majority were taking antiparkinsonian medications (95.9%), with an average LEDD of 816.44 (SD = 629.69), and the most commonly taken medication was levodopa (84.7%).

3.2. Poorer Quality of Life Correlates with NMS and Constipation

Within the cohort, nonmotor symptoms of PD, measured by the UPDRS Part I, were significantly correlated with a poorer quality of life, as determined by the PDQ-39 score (r = 0.616, ; Figure 1(a)). To determine the effect of constipation on QoL, the cohort was grouped based on multiple measures of constipation (Figure 1). When grouped by the frequency of bowel movements per day, with less than once a day grouped into the “constipated” group, and once or more into the “not constipated” group, individuals who passed less than one bowel movement a day trended towards a lower quality of life (; Figure 1(b)). When grouped by the Bristol Stool Chart rating of their bowel movements, individuals who rated their bowel movements as Types 1 and 2 were grouped into the “constipated” group, and those who rated Types 3–7 into the “not constipated” group. Participants who were grouped into the “constipated” group also trended towards a poorer quality of life than those grouped into the “not constipated” group (; Figure 1(c)). Participants were also asked whether they considered themselves to be constipated or not constipated in the self-reported constipation question, and those that considered themselves to be constipated had a significantly poorer quality of life than those who did not consider themselves constipated (; Figure 1(d)). Lastly, when all measures of constipation were combined into one variable, those that were classed as “constipated” had a significantly poorer quality of life than those who were not classed as constipated (; Figure 1(e)).

(a)

(b)

(c)

(d)

(e)

Univariate correlations showed significant associations between LEDD (r = 0.347, ) and disease duration (r = .468, ) with quality of life. As such, these factors were incorporated as covariates into GLM models looking at the above constipation measures (Table 2). GLMs revealed significant associations between the “self-reported constipation question,” and poorer quality of life in both naïve () and covariate corrected models (). When all three constipation questions were combined, results also demonstrated a significant association with poorer quality of life in both naïve () and corrected models ().

3.3. Poorer Quality of Life is Associated with GSRS Symptoms and Domains

Although the total gastrointestinal symptom score was not significantly associated with poorer quality of life, linear regression models showed that there was an association with specific gastrointestinal symptoms and symptom domains (Table 3). In the naïve models, increased eructation (), decreased passage of stools (), feeling of incomplete evacuation (), and the hypoactive GI symptom domain () were all significantly associated with poorer QoL; while in the corrected models, increased flatus (), and increased eructation () were also both significantly associated with poorer QoL.

4. Discussion

Previous QoL studies in Parkinson’s disease have focused largely on the impact of NMS, such as sleep disturbances and cognitive impairment [13–16], rather than the range of gastrointestinal and other symptoms that PwP may experience. In the current study, we investigated various measures of constipation and their relationship with QoL in an Australian cohort of PwP and found that suffering from constipation was significantly associated with a reduced QoL as measured with the PDQ-39 instrument. We went on to further explore the relationship between other gastrointestinal symptoms and QoL using the comprehensive Gastrointestinal Symptom Rating Scale (GSRS), which has previously been used to evaluate the frequency and severity of gastrointestinal symptoms in assorted clinical settings [32, 34–45], but not in a QoL study in PwP. Our findings confirmed that, in addition to constipation and other symptoms of gastrointestinal hypomotility, a number of other gastrointestinal symptoms that are not included in current clinical assessment protocols also had a negative impact on QoL.

The UPDRS Part I is a measure of nonmotor activities of daily living and gives a broad overview of nonmotor symptoms experienced by the individual. As NMS are so prevalent in PwP, it is not surprising that we found a significant correlation between increasing difficulties with nonmotor symptoms and a poorer quality of life. These results confirmed similarly reported associations in various PwP populations where NMS were found to be a significant burden to QoL [1, 5, 9, 11, 13–16, 46, 47]. However, as the UPDRS Part I is very broad, it is also superficial in terms of measuring the burden of gastrointestinal symptoms, with only a single question relating to constipation, thereby overlooking the plethora of other gastrointestinal symptoms experienced by PwP. To this end, we therefore investigated the impact of constipation on the QoL of PwP using multiple measures.

The three individual constipation measures utilised in this study were, frequency of defecation, consistency of stool passed using the Bristol Stool Chart, and a question gauging whether participants considered themselves to be constipated or not (referred to as “self-reported constipation”). All three individual constipation measures were also grouped into one combined measure for constipation. All four measures revealed a trend towards constipation being associated with a poorer quality of life, with both the GSRS question and combined measures reaching statistical significance, even after adjusting for LEDD and disease duration. Although constipation is generally accepted as being one of the earliest prodromal symptoms in PwP [48], it is still considered a “taboo” topic by many individuals [11], and is thus less likely to be reported, and therefore, to remain untreated [5], and to significantly impact on QoL [12]. This is consistent with the findings of a study that reported a discrepancy of 76% between objectives versus subjectively reported constipation in a population of PwP [10].

In our study, we found that individual gastrointestinal symptoms, other than constipation also contributed significantly to a poorer QoL. These included increased eructation, decreased passage of stools, a feeling of incomplete evacuation, and increased flatus. The impact of these symptoms is compounded further by being more prevalent in PwP [32], contributing to an added burden on QoL that is disease specific. Thus, these results shed light on a group of symptoms that are being overlooked in relation to their contribution to QoL and that may be amenable to treatment in order to improve the QoL of PwP.

Parkinson’s disease has been associated with a high burden of gastrointestinal dysfunction and comorbidities, in particular constipation and reduced colonic transit time, affecting up to 80% of all PwP [48, 49]. Furthermore, the severity of these GIS has been found to increase with the progression of the disease [50, 51]. Constipation, delayed gastric emptying, and changes in stool’s consistency have also been linked with more rapid and severe motor and cognitive decline in PD [28, 32, 52]. In addition, an association between PD and inflammatory bowel diseases (e.g., Crohn’s disease, ulcerative colitis, and irritable bowel syndrome) has been reported in assorted populations [22, 53]. Together, it is thought that, as a consequence of disease pathology, the function of the enteric nervous system can become progressively impaired in PwP [54–56]. This can result in impaired intestinal mobility and further exacerbation of gastrointestinal dysfunction as the disease progresses [57]. Thus, coinciding with evidence that gastrointestinal NMS can have considerable effects on the quality of life of PwP as well as placing a heavy burden on their carers [58].

5. Conclusions

In the present study, we have carried out an in-depth analysis of the frequency and impact of GIS on health-related QoL in a cohort of clinic-attending PwP. In addition to confirming the significant role of constipation and other symptoms of gastrointestinal hypomotility, our findings highlight a number of other GIS that are not commonly reported, that may also have significant effects on patient QoL. The results are consistent with the notion that current standard PD assessments do not comprehensively cover the full range of GIS [5, 32] and that individuals with PD are less likely to report GIS when not directly probed [11], meaning these symptoms are often overlooked, and may remain untreated, and contribute to poorer QoL. Thus, early identification and treatment of GIS in PwP has the potential to result in a significant improvement in QoL. Furthermore, it could help facilitate the development of more effective therapies to improve symptom management, and provide potential for developing a new diagnostic framework for recognising GIS in patients with early motor manifestations, or in the prodromal stages of the disease.

Data Availability

The data are available upon reasonable request from the corresponding author.

Conflicts of Interest

The authors declare that there are no conflicts of interest relevant to this work.

Acknowledgments

The authors would like to thank Ms. Sue Walters and the Perron Clinic Team for providing assessment training and unmatched logistical support, as well as Professor Soumya Ghosh for providing access to participants through the Perron Movement Disorders Clinic and would also like to thank Professor Malcolm Horne and Ms. Sarah Osborne for making it possible to recruit participants through the St Vincent’s Hospital Movement Disorders Clinic and for their generous support. This study was funded by the Parkinson’s WA Zrinski Research Grant 2019, Perron Institute of Neurological and Translational Science, and The University of Notre Dame Australia. This research was carried out while JEK was in receipt of a Perron Prestige Scholarship and a Research Training Program Scholarship at The University of Western Australia.

References

C. Pont-Sunyer, A. Hotter, C. Gaig et al., “The onset of nonmotor symptoms in Parkinson's disease (the onset pd study),” Movement Disorders, vol. 30, no. 2, pp. 229–237, 2015.
View at: Publisher Site | Google Scholar
D. M. Swallow, M. A. Lawton, K. A. Grosset et al., “Variation in recent onset Parkinson's disease: implications for prodromal detection,” Journal of Parkinson's Disease, vol. 6, no. 2, pp. 289–300, 2016.
View at: Publisher Site | Google Scholar
T. K. Khoo, A. J. Yarnall, G. W. Duncan et al., “The spectrum of nonmotor symptoms in early Parkinson disease,” Neurology, vol. 80, no. 3, pp. 276–281, 2013.
View at: Publisher Site | Google Scholar
M. Lubomski, R. L. Davis, and C. M. Sue, “Gastrointestinal dysfunction in Parkinson's disease,” Journal of Neurology, vol. 267, no. 5, pp. 1377–1388, 2020.
View at: Publisher Site | Google Scholar
D. A. Gallagher, A. J. Lees, and A. Schrag, “What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?” Movement Disorders, vol. 25, no. 15, pp. 2493–2500, 2010.
View at: Publisher Site | Google Scholar
M. A. Bock, E. G. Brown, L. Zhang, and C. Tanner, “Association of motor and nonmotor symptoms with health-related quality of life in a large online cohort of people with Parkinson disease,” Neurology, vol. 98, no. 22, pp. e2194–e2203, 2022.
View at: Publisher Site | Google Scholar
T. Who, “The world health organization quality of life assessment (whoqol): position paper from the world health organization,” Social Science & Medicine, vol. 41, pp. 1403–1409, 1995.
View at: Publisher Site | Google Scholar
S. Rahman, H. J. Griffin, N. P. Quinn, and M. Jahanshahi, “Quality of life in Parkinson's disease: the relative importance of the symptoms,” Movement Disorders, vol. 23, no. 10, pp. 1428–1434, 2008.
View at: Publisher Site | Google Scholar
N. Malek, M. A. Lawton, K. A. Grosset et al., “Autonomic dysfunction in early Parkinson's disease: results from the United Kingdom tracking Parkinson's study,” Mov Disord Clin Pract, vol. 4, pp. 509–516, 2017.
View at: Publisher Site | Google Scholar
K. Knudsen, T. D. Fedorova, A. C. Bekker et al., “Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson's disease: a colon transit and volume study,” Journal of Parkinson's Disease, vol. 7, no. 2, pp. 359–367, 2017.
View at: Publisher Site | Google Scholar
J. Kaye, H. Gage, A. Kimber, L. Storey, and P. Trend, “Excess burden of constipation in Parkinson's disease: a pilot study,” Movement Disorders, vol. 21, no. 8, pp. 1270–1273, 2006.
View at: Publisher Site | Google Scholar
A. Sauerbier and K. R. Chaudhuri, “Non-motor symptoms: the core of multi-morbid Parkinson's disease,” British Journal of Hospital Medicine, vol. 75, no. 1, pp. 18–24, 2014.
View at: Publisher Site | Google Scholar
Y. He, Y. Tian, H. Han et al., “The path linking disease severity and cognitive function with quality of life in Parkinson's disease: the mediating effect of activities of daily living and depression,” Health and Quality of Life Outcomes, vol. 19, no. 1, p. 92, 2021.
View at: Publisher Site | Google Scholar
A. Schonenberg, H. M. Zipprich, U. Teschner, J. Grosskreutz, O. W. Witte, and T. Prell, “Impact of subthreshold depression on health-related quality of life in patients with Parkinson's disease based on cognitive status,” Health and Quality of Life Outcomes, vol. 19, no. 1, p. 107, 2021.
View at: Publisher Site | Google Scholar
C. Liguori, V. De Franco, R. Cerroni et al., “Sleep problems affect quality of life in Parkinson's disease along disease progression,” Sleep Medicine, vol. 81, pp. 307–311, 2021.
View at: Publisher Site | Google Scholar
D. Santos-Garcia, E. S. Castro, T. de Deus Fonticoba et al., “Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in Parkinson's disease,” Journal of Geriatric Psychiatry and Neurology, vol. 34, no. 6, pp. 642–658, 2021.
View at: Publisher Site | Google Scholar
K. L. Adams-Carr, J. P. Bestwick, S. Shribman, A. Lees, A. Schrag, and A. J. Noyce, “Constipation preceding Parkinson's disease: a systematic review and meta-analysis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 87, no. 7, pp. 710–716, 2016.
View at: Publisher Site | Google Scholar
M. G. Cersosimo, G. B. Raina, C. Pecci et al., “Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms,” Journal of Neurology, vol. 260, no. 5, pp. 1332–1338, 2013.
View at: Publisher Site | Google Scholar
A. T. Nair, V. Ramachandran, N. M. Joghee, S. Antony, and G. Ramalingam, “Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson's disease: a critical review,” J Neurogastroenterol Motil, vol. 24, no. 1, pp. 30–42, 2018.
View at: Publisher Site | Google Scholar
S. W. Lai, Y. H. Kuo, and K. F. Liao, “Increased risk of Parkinson disease in inflammatory bowel disease patients,” Inflammatory Bowel Diseases, vol. 25, no. 10, pp. e125–e126, 2019.
View at: Publisher Site | Google Scholar
H. S. Lee, E. Lobbestael, S. Vermeire, J. Sabino, and I Cleynen, “Inflammatory bowel disease and Parkinson's disease: common pathophysiological links,” Gut, vol. 70, no. 2, pp. 408–417, 2021.
View at: Publisher Site | Google Scholar
M. Villumsen, S. Aznar, B. Pakkenberg, T. Jess, and T. Brudek, “Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014,” Gut, vol. 68, no. 1, pp. 18–24, 2019.
View at: Publisher Site | Google Scholar
F. Hopfner, A. Kunstner, S. H. Muller et al., “Gut microbiota in Parkinson disease in a northern German cohort,” Brain Research, vol. 1667, pp. 41–45, 2017.
View at: Publisher Site | Google Scholar
J. E. Kenna, E. G. Chua, M. Bakeberg et al., “Changes in the gut microbiome and predicted functional metabolic effects in an australian Parkinson's disease cohort,” Frontiers in Neuroscience, vol. 15, Article ID 756951, p. 41, 2021.
View at: Publisher Site | Google Scholar
V. A. Petrov, I. V. Saltykova, I. A. Zhukova et al., “Analysis of gut microbiota in patients with Parkinson's disease,” Bulletin of Experimental Biology and Medicine, vol. 162, no. 6, pp. 734–737, 2017.
View at: Publisher Site | Google Scholar
D. Pietrucci, R. Cerroni, V. Unida et al., “Dysbiosis of gut microbiota in a selected population of Parkinson's patients,” Parkinsonism & Related Disorders, vol. 65, pp. 124–130, 2019.
View at: Publisher Site | Google Scholar
Y. Qian, X. Yang, S. Xu et al., “Alteration of the fecal microbiota in Chinese patients with Parkinson's disease,” Brain, Behavior, and Immunity, vol. 70, pp. 194–202, 2018.
View at: Publisher Site | Google Scholar
M. M. Unger, J. Spiegel, K. U. Dillmann et al., “Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls,” Parkinsonism & Related Disorders, vol. 32, pp. 66–72, 2016.
View at: Publisher Site | Google Scholar
M. Camacho, J. C. Greenland, and C. H. Williams Gray, “The gastrointestinal dysfunction scale for Parkinson's disease,” Movement Disorders, vol. 36, no. 10, pp. 2358–2366, 2021.
View at: Publisher Site | Google Scholar
A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 55, no. 3, pp. 181–184, 1992.
View at: Publisher Site | Google Scholar
C. L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke, “Systematic review of levodopa dose equivalency reporting in Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2649–2653, 2010.
View at: Publisher Site | Google Scholar
J. E. Kenna, M. C. Bakeberg, A. M. Gorecki et al., “Characterization of gastrointestinal symptom type and severity in Parkinson's disease: a case-control study in an australian cohort,” Mov Disord Clin Pract, vol. 8, no. 2, pp. 245–253, 2021.
View at: Publisher Site | Google Scholar
E. Jani Bmarsicano, “Constipation: evaluation and management,” Missouri Medicine, vol. 115, pp. 236–240, 2018.
View at: Google Scholar
E. Dimenas, G. Carlsson, H. Glise, B. Israelsson, and I. Wiklund, “Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease,” Scandinavian Journal of Gastroenterology, vol. 31, no. 221, pp. 8–13, 1996.
View at: Publisher Site | Google Scholar
P. Karling, M. Maripuu, M. Wikgren, R. Adolfsson, and K. F. Norrback, “Association between gastrointestinal symptoms and affectivity in patients with bipolar disorder,” World Journal of Gastroenterology, vol. 22, no. 38, pp. 8540–8548, 2016.
View at: Publisher Site | Google Scholar
D. Khanna, V. Nagaraja, H. Gladue, W. Chey, M. Pimentel, and T. Frech, “Measuring response in the gastrointestinal tract in systemic sclerosis,” Current Opinion in Rheumatology, vol. 25, no. 6, pp. 700–706, 2013.
View at: Publisher Site | Google Scholar
K. R. Kulich, C. Calabrese, F. Pacini, S. Vigneri, J. Carlsson, and I. K. Wiklund, “Psychometric validation of the Italian translation of the gastrointestinal symptom-rating scale and quality of life in reflux and dyspepsia questionnaire in patients with gastro-oesophageal reflux disease,” Clinical Drug Investigation, vol. 24, no. 4, pp. 205–215, 2004.
View at: Publisher Site | Google Scholar
K. R. Kulich, A. Madisch, F. Pacini et al., “Reliability and validity of the gastrointestinal symptom rating scale (gsrs) and quality of life in reflux and dyspepsia (qolrad) questionnaire in dyspepsia: a six-country study,” Health and Quality of Life Outcomes, vol. 6, no. 1, p. 12, 2008.
View at: Publisher Site | Google Scholar
B. Ljotsson, M. Jones, N. J. Talley, L. Kjellstrom, L. Agreus, and A. Andreasson, “Discriminant and convergent validity of the gsrs-ibs symptom severity measure for irritable bowel syndrome a population study,” United European Gastroenterol, vol. 8, no. 3, pp. 284–292, 2020.
View at: Publisher Site | Google Scholar
D. A. Revicki, M. Wood, I. Wiklund, and J. Crawley, “Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease,” Quality of Life Research An International Journal of Quality of Life Aspects of Treatment Care and Rehabilitation, vol. 7, no. 1, pp. 75–83, 1998.
View at: Publisher Site | Google Scholar
G. S. Souza, F. A. H. Sardá, E. B. Giuntini, I. Gumbrevicius, M. B. Morais, and E. Wd Menezes, “Translation and validation of the brazilian Portuguese version of the gastrointestinal symptom rating scale (gsrs) questionnaire,” Arquivos de Gastroenterologia, vol. 53, no. 3, pp. 146–151, 2016.
View at: Publisher Site | Google Scholar
J. Svedlund, I. Sjdin, and G. Dotevall, “Gsrs--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease,” Digestive Diseases and Sciences, vol. 33, no. 2, pp. 129–134, 1988.
View at: Publisher Site | Google Scholar
S. B. Bayer, C. M. Frampton, R. B. Gearry, and G. Barbara, “Habitual green kiwifruit consumption is associated with a reduction in upper gastrointestinal symptoms - a systematic scoping review,” Advances in Nutrition, vol. 13, no. 3, pp. 846–856, 2022.
View at: Publisher Site | Google Scholar
H. M. LoTurco, E. M. Carter, D. E. McInerney, and C. L. Raggio, “Patient-reported prevalence of gastrointestinal issues in the adult skeletal dysplasia population with a concentration on osteogenesis imperfecta,” American Journal of Medical Genetics, Part A, vol. 188, no. 5, pp. 1435–1442, 2022.
View at: Publisher Site | Google Scholar
C. Yi, X. Wang, H. Ye, J. Lin, and X. Yang, “Patient-reported gastrointestinal symptoms in patients with peritoneal dialysis: the prevalence, influence factors and association with quality of life,” BMC Nephrology, vol. 23, no. 1, p. 99, 2022.
View at: Publisher Site | Google Scholar
G. D. Kuhlman, J. L. Flanigan, S. A. Sperling, and M. J. Barrett, “Predictors of health-related quality of life in Parkinson's disease,” Parkinsonism & Related Disorders, vol. 65, pp. 86–90, 2019.
View at: Publisher Site | Google Scholar
W. M. Liu, R. J. Lin, R. L. Yu, C. H. Tai, C. H. Lin, and R. M. Wu, “The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in taiwan,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 2865–2873, 2015.
View at: Publisher Site | Google Scholar
R. B. Postuma, D. Aarsland, P. Barone et al., “Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease,” Movement Disorders, vol. 27, no. 5, pp. 617–626, 2012.
View at: Publisher Site | Google Scholar
A. Fasano, N. P. Visanji, L. W. C. Liu, A. E. Lang, and R. F. Pfeiffer, “Gastrointestinal dysfunction in Parkinson's disease,” The Lancet Neurology, vol. 14, no. 6, pp. 625–639, 2015.
View at: Publisher Site | Google Scholar
S. Y. Liu, P. Chan, and A. J. Stoessl, “The underlying mechanism of prodromal pd: insights from the parasympathetic nervous system and the olfactory system,” Translational Neurodegeneration, vol. 6, no. 1, p. 4, 2017.
View at: Publisher Site | Google Scholar
Q. J. Yu, S. Y. Yu, L. J. Zuo et al., “Parkinson disease with constipation: clinical features and relevant factors,” Scientific Reports, vol. 8, no. 1, p. 567, 2018.
View at: Publisher Site | Google Scholar
M. Camacho, A. D. Macleod, J. Maple-Grodem et al., “Early constipation predicts faster dementia onset in Parkinson's disease,” NPJ Parkinsons Dis, vol. 7, no. 1, p. 45, 2021.
View at: Publisher Site | Google Scholar
S. W. Lai, K. F. Liao, C. L. Lin, and F. C. Sung, “Irritable bowel syndrome correlates with increased risk of Parkinson's disease in taiwan,” European Journal of Epidemiology, vol. 29, no. 1, pp. 57–62, 2014.
View at: Publisher Site | Google Scholar
F. Baldini, J. Hertel, E. Sandt et al., “Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions,” BMC Biology, vol. 18, no. 1, p. 62, 2020.
View at: Publisher Site | Google Scholar
C. Challis, A. Hori, T. R. Sampson et al., “Gut-seededalpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice,” Nature Neuroscience, vol. 23, no. 3, pp. 327–336, 2020.
View at: Publisher Site | Google Scholar
U. Raval, J. M. Harary, E. Zeng, and G. M. Pasinetti, “The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders,” Expert Review of Neurotherapeutics, vol. 20, no. 7, pp. 673–686, 2020.
View at: Publisher Site | Google Scholar
A. Mulak, “Brain-gut-microbiota axis in Parkinson's disease,” World Journal of Gastroenterology, vol. 21, no. 37, pp. 10609–10620, 2015.
View at: Publisher Site | Google Scholar
M. S. Cirstea, A. C. Yu, E. Golz et al., “Microbiota composition and metabolism are associated with gut function in Parkinson's disease,” Movement Disorders, vol. 35, no. 7, pp. 1208–1217, 2020.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Jade E. Kenna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

460

Downloads

445

Citations